Immunological research landscapes and emerging immune mechanisms in HIV/HBV co-infection: a bibliometric analysis (2014–2024)
-
By
-
Ai Peng
-
Khalid Waleed
-
Liping Qiu
-
Li Wang
-
Xiaoqin Tong
-
Zhibin Tu
-
Zhikang Li
-
Yiting Cui
-
Fei Hu
-
Shu Yang
-
Liang Lu
-
Peng Huang
-
May 14, 2026
-
Clinical Scorecard: Exploring Immunological Trends and Novel Immune Mechanisms in Co-infection of HIV and HBV: A Bibliometric Study (2014–2024)
At a Glance
| Category | Detail |
|---|
| Condition | HIV and HBV co-infection |
| Key Mechanisms | Immune dysregulation, chronic immune activation, CD4+ T-cell dysfunction |
| Target Population | Individuals co-infected with HIV and HBV |
| Care Setting | Global health settings, particularly in high-burden regions |
Key Highlights
- Significant immune dysregulation in HIV/HBV co-infection
- Increased research focus on immunological outcomes post-2017
- Emerging themes include immune-mediated hepatic injury and chronic inflammation
- Discrepancies in research efforts between high-burden and affluent regions
- Need for enhanced immune-monitoring methodologies
Guideline-Based Recommendations
Diagnosis
- Screening for HBV in HIV-positive individuals is essential.
Management
- Antiretroviral therapy (ART) strategies should consider HBV co-infection.
Monitoring & Follow-up
- Regular immune function assessments and liver health monitoring are recommended.
Risks
- Increased risk of liver fibrosis, cirrhosis, and hepatocellular carcinoma.
Patient & Prescribing Data
Individuals living with HIV/HBV co-infection, particularly in low- and middle-income countries
Tenofovir-based therapies are significant but require careful monitoring for HBV.
Clinical Best Practices
- Implement comprehensive immune-monitoring protocols.
- Encourage international collaboration for research in high-burden areas.
- Focus on immunological research to inform treatment strategies.
Related Resources & Content
